Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer

Stopped early · Phase 1/Phase 2

Conditions studied: Platinum-resistant Ovarian Cancer, Platinum-resistant Fallopian Cancer, Platinum-resistant Peritoneal Cancer

In brief

This 2-part, Phase 1/2 study will test investigational cancer drugs known as CRS-207, epacadostat (IDO), and pembrolizumab (pembro). The purpose of this study is to find out how safe it is to give the investigational drugs to women with platinum-resistant ovarian, fallopian tube, or peritoneal cancer and if it helps patients with these types of cancer live longer or can help shrink or slow the growth of cancer.

Key facts

Study ID

NCT02575807

Run by

Aduro Biotech, Inc.

People needed

35

Starts

2016-03-08

Expected to finish

2018-05-08

Last updated by the study team

2019-04-04

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Histologically-confirmed disease
• Phase 1: Individuals with epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinomas who are considered to have platinum-resistant disease (progression within 6 months from completion of platinum-based chemotherapy).
• Phase 2: Individuals with epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinomas who are considered to have platinum-resistant disease (progression within 6 months from completion of a minimum of 4 platinum therapy cycles).
• Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
• Agree to provide core biopsies at baseline and at Cycle 2 Day 15
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Available archived tumor tissue for central analysis
• Adequate organ and marrow function

You may not qualify if…

• Platinum-refractory disease (progression during the first platinum-based chemotherapy)
• Major surgical procedure within 4 weeks prior to Study Day 1
• Inaccessible tumors or for whom biopsy is contraindicated
• Clinically significant ascites
• Phase 2 only: Previous treatment with >3 chemotherapy regimens for locally advanced or metastatic disease
• Active bowel obstruction, or hospitalization for bowel obstruction within 2 months prior to screening
• Require parenteral nutrition
• Hospitalization within 2 weeks prior to screening
• Received any anticancer medication or therapy in the 21 days prior to study Day 1
• Prior monoclonal antibody treatment within 4 weeks before study Day 1
• History of listeriosis or previous treatment with a listeria-based immunotherapy
• Known allergy to both penicillin and sulfa antibiotics
• Any immunodeficiency disease or immune-compromised state
• Received prior immune checkpoint inhibitors (e.g., anti-CTLA-4, anti-PD-1, anti PDL-1) and any other antibody or drug specifically targeting T-cell costimulation or an IDO inhibitor
• Pregnant or breastfeeding
• Clinically significant heart disease
• Valvular heart disease that requires antibiotic prophylaxis for prevention of endocarditis
• History of any autoimmune disease which required systemic therapy in the past 2 years
• Diagnosed with another malignancy within the past 3 years
• Currently receiving therapy with a UDP-glucuronosyltransferase 1A9 inhibitor including diclofenac, imipramine, ketoconazole, mefenamic acid, and probenecid
• Receiving monoamine oxidase inhibitor (MAOIs) or a drug which has significant MAOI activity (meperidine, linezolid, methylene blue) within the 21 days before screening
• Had prior serotonin syndrome
• Has implanted medical devices that pose high risks for colonization and cannot be easily removed

Where it is running

• Scottsdale Healthcare Hospitals DBA HonorHealth — Scottsdale, Arizona, United States
• Stanford Cancer Center — Stanford, California, United States
• University of Florida — Gainesville, Florida, United States
• Northwestern University — Chicago, Illinois, United States
• Johns Hopkins University — Baltimore, Maryland, United States
• Oregon Health and Science University — Portland, Oregon, United States
• University of Pennsylvania Health System — Philadelphia, Pennsylvania, United States
• Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
• University of Virginia Health System — Charlottesville, Virginia, United States
• Virginia Mason Medical Center — Seattle, Washington, United States
• Princess Margaret Cancer Centre — Toronto, Ontario, Canada
• CHUM - Centre Hospitalier de l'Université de Montréal — Montreal, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.